iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy

BACKGROUND: HIV therapeutic vaccination aims to improve the immune responses against HIV in order to control viral replication without the need for combined antiretroviral therapy (cART). iHIVARNA-01 is a novel vaccine combining mRNA delivery and T-cell immunogen (HTI) based on conserved targets of...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Wesley, Aerts, Joeri, Allard, Sabine, Brander, Christian, Buyze, Jozefien, Florence, Eric, van Gorp, Eric, Vanham, Guido, Leal, Lorna, Mothe, Beatriz, Thielemans, Kris, Plana, Montse, Garcia, Félipe, Gruters, Rob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580477/
https://www.ncbi.nlm.nih.gov/pubmed/31208472
http://dx.doi.org/10.1186/s13063-019-3409-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580477/
https://www.ncbi.nlm.nih.gov/pubmed/31208472
http://dx.doi.org/10.1186/s13063-019-3409-1

Ejemplares similares